Company / EPS (Basic)
Jazz Pharmaceuticals EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
$6.55
FY2025
5-year range
-$5.52 / $9.22
FY2021-FY2025
Trend
+283.0%
vs FY2024
Sector context
#8 of 208
Health Care
What the data says
EPS (Basic) changed +283% YoY in FY2025, a notable deviation from the 9-year average annual change of +61%.
Based on SEC 10-K filings.
6.55 in FY2025 with a 5-year CAGR of -2.5%. Top quartile in the Health Care sector.
Improved from $-5.52 to $6.55 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- +15.2%
- 5-Year CAGR
- -2.5%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 208This company $6.55 Sector average -$0.96
▼
+780.1% above sector average
Key checks
Key Insights
- In FY2025, eps (basic) increased 283.0% year-over-year.
- Ranks #8 out of 208 companies in the Health Care sector.
- Peak eps (basic) was recorded in FY2021.
- Lowest eps (basic) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.55 | +283.0% |
| FY2024 | -$3.58 | +35.1% |
| FY2023 | -$5.52 | -229.0% |
| FY2022 | $4.28 | -53.6% |
| FY2021 | $9.22 | +23.8% |
| FY2020 | $7.45 | -8.4% |
| FY2019 | $8.13 | +23.9% |
| FY2018 | $6.56 | +21.9% |
| FY2017 | $5.38 | +449.0% |
| FY2016 | $0.98 | -73.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026